Evidence map›Paper›PMID 41908211›Full record

ArticleEuropean urology open science2026

Familial Risks in 317 000 Patients With Prostate Cancer in Relation to Metastases and Survival-Guiding Diagnostics.

Kari Hemminki, Frantisek Zitricky, Kristina Sundquist, Jan Sundquist, Asta Försti, Akseli Hemminki, Otto Hemminki

Abstract read
In one paragraph

Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kari HemminkiBiomedical Center, Faculty of Medicine, Charles University, Pilsen, Czech Republic.
Frantisek ZitrickyBiomedical Center, Faculty of Medicine, Charles University, Pilsen, Czech Republic.
Kristina SundquistCenter for Primary Health Care Research, Lund University, Malmö, Sweden.
Jan SundquistCenter for Primary Health Care Research, Lund University, Malmö, Sweden.
Asta FörstiHopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Akseli HemminkiComprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
Otto HemminkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Swedish nationwide family and cancer data offer the largest global resource for study of familial cancer. We focus here on familial risks in prostate cancer (PC) with questions on risk in individuals from families of multiple affected members and association of familial risk with metastatic disease and survival. Methods: Familial relative risk of PC was estimated using standardized incidence ratios (SIRs) for second-generation men with a father or brother affected with PC, considering distinct groups by number and type of affected relatives. Results: Familial SIRs ranged from 2.22 (2 brothers with PC) to 11.5 (≥5 brothers with PC). The proportions of affected men increased from about 15% (2-case families) to 50% (≥5-case families). Age-incidence curves showed successively higher rates for men from multi-case families. Older patients with PC had the highest proportion of metastases at diagnosis, but in each age group, familial patients presented with a lower proportion of metastases compared with nonfamilial cases. Among brothers, the proportion of metastasis was higher in brothers first diagnosed compared with brothers with subsequent diagnosis. Survival in familial cases was better compared with nonfamilial cases among patients without metastases. Among such patients, brothers diagnosed first survived worse than subsequent brothers. Conclusions and clinical implications: The largest family study yet conducted on PC was based on 34 468 familial cases. Risk varied greatly by family constellations, emphasizing the need for a detailed family history at diagnosis as basis for clinical decision-making and genetic counseling. The reported high risks should encourage implementation of familial risk into schemes for PC screening. Patient summary: Patients with prostate cancer often have a relative who has prostate cancer. When PC is diagnosed, it is important that the patient reports a reliable history of relatives earlier diagnosed with PC. It may influence his treatment.

Indexed as

Age of onsetEarly onsetFamilial riskGermline geneticsHeredity

Identifiers

PMID41908211
PMCPMC13019772

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.